Co-Director, Brain Tumor Program
Director, Solid Tumor Programs
Co-Director, Retinoblastoma Program
Texas Children’s Cancer Center
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
6701 Fannin Street, Suite 1510.15
Houston, TX 77030
Dr. Murali Chintagumpala is a Co-Director of the Brain Tumor Program, Director of the Solid Tumor Programs, and Co-Director of the Retinoblastoma Program. He oversees all clinical and clinical research activities involving children with brain tumors and solid tumors at Texas Children’s Cancer and Hematology Center. His specific interests include the management of children with all brain tumors, retinoblastoma, bone tumors, and kidney tumors.
Dr. Murali’s extensive background in treating children with brain tumors has led him to become the Principal Investigator representing Baylor College of Medicine in the Pediatric Brain Tumor Consortium. He serves as member of the Brain Tumor Committee within the Children’s Oncology Group (COG) and serves an active role at Texas Children’s Cancer Center where he is Co-Director of our Brain Tumor Program.
In addition, Dr. Murali is a Clinical Co-Director of the Retinoblastoma Program and Chair of the Retinoblastoma Center of Houston. At the national level, he serves as chair of the Retinoblastoma Committee within the Children’s Oncology Group and is a leader in conducting clinical trials involving children with retinoblastoma.
As Director of our Solid Tumor Programs, he is an experienced clinician expert in the management of children with bone tumors, liver tumors and kidney tumors. He is the principal investigator of a multi-institutional study designed to improve survival in patients with osteosarcoma as part of the Bone Tumor Program.
He is board certified in pediatric Hematology/Oncology by the American Board of Pediatrics.
Dr. Murali is a graduate of Madras Medical College in India. He then completed his residency at Columbus Hospital in Chicago, Illinois, then attended Baylor College of Medicine where he graduated from the Fellowship Program in Pediatric Hematology/Oncology.
Chair, Retinoblastoma Committee, Children’s Oncology Group (COG)
Member, Brain Tumor Committee, Children’s Oncology Group (COG)
Member, Renal Tumor Committee, Children’s Oncology Group (COG)
Member, Children’s Oncology Group (COG)
Member, Pediatric Brain Tumor Consortium (PBTC)
Member, American Society of Clinical Oncology (ASCO)
Member, American Society of Pediatric Hematology and Oncology (ASPHO)